Today, Biostar Pharmaceuticals, a leading provider of pharmaceuticals and health supplements, like the Company’s popular OTC offering for chronic hepatitis B (Xin AoXing Oleanolic Acid Capsule), reported special selection (at a January 8th ceremony) by the PLA’s Fourth Military Medical University (FMMU) for cooperation in ongoing research and product development activities.
The FMMU has been a major force in the Chinese military medical landscape since its formation in 1954 (out of the 4th and 5th Military Medical Colleges), serving a vital role as one of only a handful of key institutions for training middle- to high-level medical personnel for the People’s Liberation Army. Currently, the FMMU is comprised of a variety of specialized areas, including basic and aerospace medicine, as well as nursing, pharmacology, biomedical engineering, stomatology research (oral diseases), military services and statistics. In addition to the several college buildings, the FMMU also operates the First and Second Affiliated General Hospitals, as well as the Stomatological Hospital.
Chairman and CEO of BSPM, Ronghua Wang, telegraphed shareholder excitement about the Company being selected as one of only nine Chinese pharma companies for such a prestigious cooperation agreement with the FMMU; noting Biostar’s lean architecture and vertically integrated business model, deep R&D competencies, manufacturing and marketing prowess. Wang reaffirmed the Company’s commitment to increasing shareholder value through expanded product range, improved sales volume and overall efficiency/profitability through periods of sustained growth.
The audience of some 3k doctors, professors and professional members of the Chinese medical community, including executives from over 500 pharma companies, listened intently as Wang detailed projected collaboration between BSPM and the FMMU in advancing the products covered under the agreement through Phase IV clinical trials. Wang also indicated that prescribed military guidelines would entail R&D for select products intended for use solely by the PRC and the FMMU’s three hospitals. The Zushima pain suppressant spray BSPM developed for the military is a good example of the approach as well as the results that will be employed moving forward.
Wang went on to extol the Company’s years of dedicated effort by BSPM personnel in nurturing strategic relationships with key universities throughout China, like the Shaanxi College of Traditional Chinese Medicine and Shaanxi University of Science and Technology, as well as the Northwest University College of Life Science. This diligent effort, in conjunction with the newly acquired FMMU cooperation, has positioned BSPM for unprecedented growth on the surging projections in the pharma sector.
Huge news for BSPM, being selected out of so many candidates in the FMMU’s rigorous screening process, and it all came down to the incredibly positive track record set by the Company in everything from R&D milestones to clinical trial completion and product efficacy.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
